SEGMENT AND ENTERPRISE-WIDE INFORMATION

3 Months Ended

Jul. 01, 2017

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

SEGMENT AND ENTERPRISE-WIDE INFORMATION

We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. We aggregate components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:

• Japan

• EMEA

• North America Plasma

• All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, and gains on divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

During the first quarter of fiscal 2018, management changed the cost reporting structure such that a portion of corporate expenses were reclassified into the operating segments. Accordingly, the prior year numbers have been updated to reflect this reclassification.

Selected information by business segment is presented below:

	Three Months Ended
(In thousands)	July 1, 2017			July 2, 2016
Net revenues
Japan	$	15,232		$	14,566
EMEA	43,008			45,741
North America Plasma	77,536			73,475
All Other	78,174			78,020
Net revenues before foreign exchange impact	213,950			211,802
Effect of exchange rates	(2,999		)	(1,846		)
Net revenues	$	210,951		$	209,956

	Three Months Ended
(In thousands)	July 1, 2017			July 2, 2016
Segment operating income
Japan	$	6,738		$	6,156
EMEA	8,571			8,276
North America Plasma	24,102			25,168
All Other	27,686			27,170
Segment operating income	67,097			66,770
Corporate operating expenses	(39,311		)	(46,139		)
Effect of exchange rates	(2,201		)	(1,306		)
Restructuring and turnaround costs	(2,483		)	(18,816		)
Deal amortization	(6,491		)	(7,075		)
Asset impairments	—			(1,315		)
Operating income	$	16,611		$	(7,881	)

Our products are organized into four categories for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these business units; however, no other financial information is currently available on this basis.

Net revenues by business unit are as follows:

	Three Months Ended
(In thousands)	July 1, 2017		July 2, 2016
Plasma	$	101,507	$	97,649
Blood Center	65,565		70,943
Cell Processing	26,336		26,076
Hemostasis Management	17,543		15,288
Net revenues	$	210,951	$	209,956

Net revenues generated in our principle operating regions on a reported basis are as follows:

	Three Months Ended
(In thousands)	July 1, 2017		July 2, 2016
United States	$	131,052	$	125,700
Japan	14,916		14,964
Europe	37,222		40,367
Asia	25,940		26,992
Other	1,821		1,933
Net revenues	$	210,951	$	209,956